急性虚血性脳卒中治療薬の世界市場レポート 2025年

急性虚血性脳卒中治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年には179億6,000万米ドルに成長し、CAGRは6.0%となります。予測期間の成長は、新たな治療法と医薬品パイプライン、精密医療と個別化治療、世界のヘルスケアインフラ開発、医療費の増加、遠隔医療と遠隔患者モニタリングに起因しています。予測期間の主な動向には、血栓溶解療法の進歩、神経保護剤の開発、個別化医療とバイオマーカー研究、遠隔医療と遠隔モニタリング、共同研究、戦略的パートナーシップなどが含まれます。

今後数年間における急性虚血性脳卒中治療薬市場の成長予測は、慢性疾患の有病率の増加と密接に関連しています。慢性疾患は非伝染性疾患とも呼ばれ、継続的な医療を必要とする持続的な病態であり、日常生活を制限することが多くあります。心臓病、がん、糖尿病など、死亡や身体障害の主要な原因はこのカテゴリーに属します。急性虚血性脳卒中治療薬は、血栓形成や脳卒中のリスクを軽減し、脳への血流を回復させることで、慢性疾患の管理に重要な役割を果たしています。2022年9月、世界保健機関（WHO）は、慢性疾患が原因で年間約4,100万人が死亡し、世界の死因の74％を占めていると報告しました。そのうち1,700万人は70歳になる前にこれらの疾患で命を落としているとのことです。2025年までに、人口の49％近くにあたる推定1億6,400万人の米国人が慢性疾患を抱え生活するという予測は、慢性疾患が世界の健康に与える影響の大きさを強調しています。その結果、慢性疾患の増加は急性虚血性脳卒中治療薬市場の成長を促進する重要な要因となっています。

急性虚血性脳卒中治療薬市場の成長は、高齢者人口の増加によって促進されると予測されます。この人口動向は、全人口における高齢者の割合の増加によって顕著に表れています。急性虚血性脳卒中治療薬は、このような人口動態において重要な役割を果たし、健康状態の改善、生活の質の向上、障害の減少、脳損傷の最小化、適時の再灌流、その後の脳卒中の予防、長期生存率の向上、リハビリテーションの可能性の改善につながります。例えば、米国に本部を置く非営利団体Population Reference Bureauの報告書によると、65歳以上の米国人の数は、2022年の5,800万人から2050年には8,200万人に増加し、47％増になると予測しています。さらに、この年齢層が総人口に占める割合は、同じ期間に17％から23％に上昇すると予想されています。このように、急性虚血性脳卒中治療薬市場の成長は高齢者人口の増加によって牽引されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の急性虚血性脳卒中治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の急性虚血性脳卒中治療薬市場：成長率分析
• 世界の急性虚血性脳卒中治療薬市場の実績：規模と成長、2019～2024年
• 世界の急性虚血性脳卒中治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の急性虚血性脳卒中治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性虚血性脳卒中治療薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 錠剤
• カプセル
• その他
• 世界の急性虚血性脳卒中治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の急性虚血性脳卒中治療薬市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 診断センター
• その他
• 世界の急性虚血性脳卒中治療薬市場：錠剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 即効性錠剤
• 徐放性錠剤
• 口腔内崩壊錠
• 世界の急性虚血性脳卒中治療薬市場：カプセルのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ハードシェルカプセル
• ソフトゼラチンカプセル
• 徐放性カプセル
• 世界の急性虚血性脳卒中治療薬市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射液
• 静脈内（IV）製剤
• 吸入製剤

第7章 地域別・国別分析

• 世界の急性虚血性脳卒中治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の急性虚血性脳卒中治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性虚血性脳卒中治療薬市場：競合情勢
• 急性虚血性脳卒中治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • C.H. Boehringer Sohn AG & Co. KG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• ZZ Biotech LLC
• NoNO Inc.
• Biogen Inc.
• Athersys Inc.
• Bayer AG
• Sanofi S.A.
• Pfizer Inc.
• DiaMedica Therapeutics
• Lumosa Therapeutics Co. Ltd.
• Johnson & Johnson
• Acticor Biotech
• Meridigen Biotech Co.
• Prolong Pharmaceuticals LLC
• Nanjing Yoko Biomedical Co. Ltd.
• TrueBinding Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性虚血性脳卒中治療薬市場2029年：新たな機会を提供する国
• 急性虚血性脳卒中治療薬市場2029年：新たな機会を提供するセグメント
• 急性虚血性脳卒中治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute ischemic stroke drugs are medications designed to address the medical emergency that arises when blood flow to the brain is interrupted, typically due to a blood clot. The primary goal of these drugs is to restore blood flow to the affected area of the brain and minimize potential brain damage.

These drugs are available in various forms, including tablets, capsules, and other formulations. Tablets, for instance, are solid unit-dose forms of medication that contain the necessary excipients. They consist of a blend of excipients and active ingredients, often in powder form, which is then compressed or pressed into a solid dosage. These medications are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with predominant use in hospitals, diagnostic centers, and other relevant applications.

The acute ischemic stroke drugs market research report is one of a series of new reports from The Business Research Company that provides acute ischemic stroke drugs market statistics, including acute ischemic stroke drugs industry global market size, regional shares, competitors with an acute ischemic stroke drugs market share, detailed acute ischemic stroke drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acute ischemic stroke drugs industry. This acute ischemic stroke drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute ischemic stroke drugs market size has grown strongly in recent years. It will grow from$13.5 billion in 2024 to $14.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidence of stroke, government initiatives and healthcare policies, increased awareness and education, strategic collaborations and partnerships, aging population

The acute ischemic stroke drugs market size is expected to see strong growth in the next few years. It will grow to $17.96 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine and personalized therapies, global healthcare infrastructure development, increasing healthcare expenditure, telemedicine and remote patient monitoring. Major trends in the forecast period include advancements in thrombolytic therapies, neuroprotective agents development, personalized medicine and biomarker research, telemedicine and remote monitoring, collaborations and strategic partnerships.

The anticipated growth of the acute ischemic stroke drug market in the coming years is closely linked to the increasing prevalence of chronic diseases. Chronic diseases, also referred to as non-communicable diseases, are persistent conditions requiring ongoing medical care, often limiting daily activities. Leading causes of death and disability, such as heart disease, cancer, and diabetes, fall under this category. Acute ischemic stroke drugs play a crucial role in managing chronic diseases by reducing the risk of clot formation and strokes, as well as restoring blood flow to the brain. In September 2022, the World Health Organization (WHO) reported that approximately 41 million people die annually due to chronic diseases, accounting for 74% of global deaths, with 17 million individuals succumbing to these conditions before the age of 70. The projection that an estimated 164 million Americans, nearly 49% of the population, will be living with chronic illnesses by 2025 underscores the significant impact of chronic diseases on global health. Consequently, the rise in chronic disease prevalence is a key driver fueling the growth of the acute ischemic stroke drug market.

The growth of the acute ischemic stroke drugs market is anticipated to be fueled by the rising aging population. This demographic trend is marked by a higher percentage of elderly individuals within the overall population. Drugs for acute ischemic stroke play a vital role in this demographic, leading to better health outcomes, enhanced quality of life, decreased disability, minimized brain damage, timely reperfusion, prevention of subsequent strokes, higher long-term survival rates, and improved rehabilitation possibilities. For example, a report from the Population Reference Bureau, a nonprofit organization based in the U.S., predicts that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, this age group's proportion of the total population is expected to climb from 17% to 23% over the same timeframe. Consequently, the growth of the acute ischemic stroke drugs market is being driven by the increasing aging population.

The anticipated growth of the acute ischemic stroke drugs market in the coming years is closely tied to the increasing demand for diagnostic centers. Diagnostic centers, which assess health conditions and provide necessary treatment, play a pivotal role in the timely and accurate diagnosis crucial for effective treatment of acute ischemic stroke. As of April 2022, reports from GOV.UK, a UK-based government digital service provider, indicated that 73 diagnostic centers operated, performing an additional 30,000 tests per week in 2022. Furthermore, projections suggest an increase to 160 community diagnostic centers by 2025. This surge in demand for diagnostic centers underscores their significant role in the diagnosis and management of acute ischemic stroke, thereby driving the growth of the associated drug market.

Key players in the acute ischemic stroke drug market are focusing on creating innovative formulations, such as sublingual versions of edaravone and dexborneol. These sublingual formulations are designed to be placed under the tongue for quick absorption into the bloodstream, leveraging the antioxidant and anti-inflammatory properties of both ingredients to enhance treatment effectiveness. For example, in October 2024, Simcere Pharmaceutical, a pharmaceutical company based in China, received breakthrough therapy designation for Sanbexin, a sublingual formulation of edaravone and dexborneol aimed at treating acute ischemic stroke (AIS). This designation followed encouraging outcomes from the TASTE-SL phase 3 clinical trial (NCT04950920), which revealed that 64.4% of patients treated with Sanbexin achieved a modified Rankin Scale (mRS) score of <=1 at 90 days, in contrast to 54.7% in the placebo group. This treatment can be administered outside of hospital environments, with the goal of minimizing disability and improving patient outcomes in AIS cases.

Major players in the acute ischemic stroke drugs market are prioritizing strategic partnerships to drive revenue growth. Strategic partnerships involve collaborative alliances between independent entities to achieve shared objectives and mutual benefits. An illustrative example is the partnership between Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, and Pharmazz Inc., a U.S. biopharmaceutical company. This collaboration, announced in September 2023, aims to address the urgent demand for efficient therapies for cerebral ischemic stroke in the Indian market. The partnership introduces Sovateltide, an innovative medication designed to treat acute cerebral ischemic stroke, marking a significant development in the acute ischemic stroke drugs market.

Major companies operating in the acute ischemic stroke drugs market include F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis

North America was the largest region in the acute ischemic stroke drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the acute ischemic stroke drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The acute ischemic stroke drugs market consists of sales of alteplase drugs, antiplatelet drugs, clopidogrel drugs, aspirin drugs, and anticoagulant drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Ischemic Stroke Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute ischemic stroke drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute ischemic stroke drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute ischemic stroke drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Tablet; Capsule; Other Types
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Hospitals; Diagnostic Centers; Other Applications
• Subsegments:
• 1) By Tablet: Immediate Release Tablets; Extended Release Tablets; Orally Disintegrating Tablets
• 2) By Capsule: Hard Shell Capsules; Soft Gelatin Capsules; Extended Release Capsules
• 3) By Other Types: Injectable Solutions; Intravenous (IV) Preparations; Inhalation Formulations
• Companies Mentioned: F. Hoffmann-La Roche AG; C.H. Boehringer Sohn AG & Co. KG; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Ischemic Stroke Drugs Market Characteristics

3. Acute Ischemic Stroke Drugs Market Trends And Strategies

4. Acute Ischemic Stroke Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Acute Ischemic Stroke Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Ischemic Stroke Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Ischemic Stroke Drugs Market Growth Rate Analysis
• 5.4. Global Acute Ischemic Stroke Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Ischemic Stroke Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Ischemic Stroke Drugs Total Addressable Market (TAM)

6. Acute Ischemic Stroke Drugs Market Segmentation

• 6.1. Global Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Capsule
• Other Types
• 6.2. Global Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Other Applications
• 6.4. Global Acute Ischemic Stroke Drugs Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate Release Tablets
• Extended Release Tablets
• Orally Disintegrating Tablets
• 6.5. Global Acute Ischemic Stroke Drugs Market, Sub-Segmentation Of Capsule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hard Shell Capsules
• Soft Gelatin Capsules
• Extended Release Capsules
• 6.6. Global Acute Ischemic Stroke Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Solutions
• Intravenous (IV) Preparations
• Inhalation Formulations

7. Acute Ischemic Stroke Drugs Market Regional And Country Analysis

• 7.1. Global Acute Ischemic Stroke Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Ischemic Stroke Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Ischemic Stroke Drugs Market

• 8.1. Asia-Pacific Acute Ischemic Stroke Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Ischemic Stroke Drugs Market

• 9.1. China Acute Ischemic Stroke Drugs Market Overview
• 9.2. China Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Ischemic Stroke Drugs Market

• 10.1. India Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Ischemic Stroke Drugs Market

• 11.1. Japan Acute Ischemic Stroke Drugs Market Overview
• 11.2. Japan Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Ischemic Stroke Drugs Market

• 12.1. Australia Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Ischemic Stroke Drugs Market

• 13.1. Indonesia Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Ischemic Stroke Drugs Market

• 14.1. South Korea Acute Ischemic Stroke Drugs Market Overview
• 14.2. South Korea Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Ischemic Stroke Drugs Market

• 15.1. Western Europe Acute Ischemic Stroke Drugs Market Overview
• 15.2. Western Europe Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Ischemic Stroke Drugs Market

• 16.1. UK Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Ischemic Stroke Drugs Market

• 17.1. Germany Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Ischemic Stroke Drugs Market

• 18.1. France Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Ischemic Stroke Drugs Market

• 19.1. Italy Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Ischemic Stroke Drugs Market

• 20.1. Spain Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Ischemic Stroke Drugs Market

• 21.1. Eastern Europe Acute Ischemic Stroke Drugs Market Overview
• 21.2. Eastern Europe Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Ischemic Stroke Drugs Market

• 22.1. Russia Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Ischemic Stroke Drugs Market

• 23.1. North America Acute Ischemic Stroke Drugs Market Overview
• 23.2. North America Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Ischemic Stroke Drugs Market

• 24.1. USA Acute Ischemic Stroke Drugs Market Overview
• 24.2. USA Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Ischemic Stroke Drugs Market

• 25.1. Canada Acute Ischemic Stroke Drugs Market Overview
• 25.2. Canada Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Ischemic Stroke Drugs Market

• 26.1. South America Acute Ischemic Stroke Drugs Market Overview
• 26.2. South America Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Ischemic Stroke Drugs Market

• 27.1. Brazil Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Ischemic Stroke Drugs Market

• 28.1. Middle East Acute Ischemic Stroke Drugs Market Overview
• 28.2. Middle East Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Ischemic Stroke Drugs Market

• 29.1. Africa Acute Ischemic Stroke Drugs Market Overview
• 29.2. Africa Acute Ischemic Stroke Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Ischemic Stroke Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Ischemic Stroke Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Ischemic Stroke Drugs Market Competitive Landscape And Company Profiles

• 30.1. Acute Ischemic Stroke Drugs Market Competitive Landscape
• 30.2. Acute Ischemic Stroke Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. C.H. Boehringer Sohn AG & Co. KG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Acute Ischemic Stroke Drugs Market Other Major And Innovative Companies

• 31.1. ZZ Biotech LLC
• 31.2. NoNO Inc.
• 31.3. Biogen Inc.
• 31.4. Athersys Inc.
• 31.5. Bayer AG
• 31.6. Sanofi S.A.
• 31.7. Pfizer Inc.
• 31.8. DiaMedica Therapeutics
• 31.9. Lumosa Therapeutics Co. Ltd.
• 31.10. Johnson & Johnson
• 31.11. Acticor Biotech
• 31.12. Meridigen Biotech Co.
• 31.13. Prolong Pharmaceuticals LLC
• 31.14. Nanjing Yoko Biomedical Co. Ltd.
• 31.15. TrueBinding Inc.

32. Global Acute Ischemic Stroke Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Ischemic Stroke Drugs Market

34. Recent Developments In The Acute Ischemic Stroke Drugs Market

35. Acute Ischemic Stroke Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Acute Ischemic Stroke Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Ischemic Stroke Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Ischemic Stroke Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer